 Karen Christopher
Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract Extraction | 10 | 2025 | 98 | 5.340 |
Why?
| | Cataract | 11 | 2023 | 213 | 5.200 |
Why?
| | Keratomileusis, Laser In Situ | 4 | 2024 | 21 | 2.940 |
Why?
| | Lenses, Intraocular | 6 | 2022 | 43 | 2.920 |
Why?
| | Myopia | 5 | 2024 | 47 | 2.910 |
Why?
| | Refraction, Ocular | 5 | 2024 | 37 | 2.550 |
Why?
| | Visual Acuity | 8 | 2024 | 356 | 2.420 |
Why?
| | Lasers, Excimer | 4 | 2024 | 28 | 2.370 |
Why?
| | Phacoemulsification | 6 | 2025 | 122 | 2.250 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 19 | 1.640 |
Why?
| | Retinal Detachment | 2 | 2023 | 63 | 1.480 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 9 | 1.470 |
Why?
| | Diabetic Retinopathy | 2 | 2023 | 189 | 1.340 |
Why?
| | Intraoperative Complications | 4 | 2024 | 138 | 1.320 |
Why?
| | Blood Loss, Surgical | 2 | 2020 | 101 | 1.100 |
Why?
| | Ophthalmology | 2 | 2023 | 86 | 0.930 |
Why?
| | Aberrometry | 2 | 2021 | 9 | 0.870 |
Why?
| | Optics and Photonics | 2 | 2021 | 43 | 0.850 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 1 | 2022 | 7 | 0.800 |
Why?
| | Endothelium, Corneal | 1 | 2022 | 16 | 0.800 |
Why?
| | Retinal Perforations | 1 | 2022 | 16 | 0.750 |
Why?
| | Postoperative Complications | 6 | 2024 | 2654 | 0.720 |
Why?
| | Lens Implantation, Intraocular | 4 | 2022 | 59 | 0.710 |
Why?
| | Lens Subluxation | 1 | 2021 | 3 | 0.700 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 5 | 0.700 |
Why?
| | Corneal Neovascularization | 1 | 2020 | 15 | 0.690 |
Why?
| | Keratitis | 1 | 2020 | 15 | 0.680 |
Why?
| | Corneal Stroma | 1 | 2020 | 23 | 0.680 |
Why?
| | Eye Infections, Bacterial | 1 | 2020 | 28 | 0.670 |
Why?
| | Endophthalmitis | 1 | 2020 | 29 | 0.670 |
Why?
| | Retrospective Studies | 15 | 2024 | 15657 | 0.640 |
Why?
| | Vitreous Body | 1 | 2020 | 110 | 0.640 |
Why?
| | Hepatitis C | 1 | 2022 | 271 | 0.630 |
Why?
| | Scurvy | 1 | 2019 | 17 | 0.610 |
Why?
| | Heroin Dependence | 1 | 2019 | 33 | 0.600 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2531 | 0.570 |
Why?
| | Conjunctival Neoplasms | 1 | 2017 | 8 | 0.550 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 13 | 0.540 |
Why?
| | Follow-Up Studies | 8 | 2024 | 5131 | 0.540 |
Why?
| | Fingolimod Hydrochloride | 1 | 2017 | 40 | 0.530 |
Why?
| | Conjunctiva | 1 | 2017 | 51 | 0.530 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 76 | 0.500 |
Why?
| | Anterior Chamber | 1 | 2015 | 22 | 0.480 |
Why?
| | Internship and Residency | 2 | 2025 | 1147 | 0.430 |
Why?
| | Cytoprotection | 1 | 2013 | 56 | 0.430 |
Why?
| | Bacteria | 1 | 2020 | 858 | 0.420 |
Why?
| | alpha-Crystallin B Chain | 1 | 2013 | 24 | 0.420 |
Why?
| | Thrombocytopenia | 1 | 2015 | 200 | 0.420 |
Why?
| | Humans | 33 | 2025 | 137585 | 0.410 |
Why?
| | Crystallins | 1 | 2013 | 59 | 0.410 |
Why?
| | Aged, 80 and over | 8 | 2024 | 7635 | 0.400 |
Why?
| | Lens, Crystalline | 1 | 2013 | 125 | 0.380 |
Why?
| | Tertiary Healthcare | 2 | 2022 | 33 | 0.360 |
Why?
| | Hot Temperature | 1 | 2013 | 391 | 0.340 |
Why?
| | Artificial Intelligence | 2 | 2025 | 279 | 0.340 |
Why?
| | Cornea | 2 | 2022 | 138 | 0.340 |
Why?
| | Academic Medical Centers | 2 | 2022 | 512 | 0.290 |
Why?
| | Male | 17 | 2025 | 67762 | 0.290 |
Why?
| | Aged | 10 | 2024 | 23961 | 0.280 |
Why?
| | Oxidative Stress | 1 | 2013 | 1317 | 0.260 |
Why?
| | Clinical Competence | 2 | 2025 | 1118 | 0.250 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3715 | 0.250 |
Why?
| | Middle Aged | 9 | 2024 | 33479 | 0.240 |
Why?
| | Capsule Opacification | 2 | 2021 | 22 | 0.220 |
Why?
| | Axial Length, Eye | 1 | 2024 | 15 | 0.220 |
Why?
| | Refractive Errors | 1 | 2024 | 18 | 0.220 |
Why?
| | Ophthalmologists | 1 | 2023 | 12 | 0.210 |
Why?
| | Female | 12 | 2024 | 73304 | 0.210 |
Why?
| | Language | 2 | 2023 | 292 | 0.200 |
Why?
| | Descemet Membrane | 1 | 2022 | 5 | 0.200 |
Why?
| | Wet Macular Degeneration | 1 | 2023 | 56 | 0.200 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 82 | 0.190 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 229 | 0.190 |
Why?
| | Geographic Atrophy | 1 | 2023 | 79 | 0.190 |
Why?
| | Tissue and Organ Harvesting | 1 | 2022 | 70 | 0.190 |
Why?
| | Cell Count | 1 | 2022 | 324 | 0.190 |
Why?
| | Alanine Transaminase | 1 | 2022 | 157 | 0.190 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.180 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.180 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.180 |
Why?
| | Microscopy | 1 | 2022 | 152 | 0.180 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.180 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.180 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1266 | 0.170 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.170 |
Why?
| | Treatment Outcome | 4 | 2024 | 10811 | 0.170 |
Why?
| | Intraoperative Period | 1 | 2020 | 59 | 0.170 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.170 |
Why?
| | Hepacivirus | 1 | 2022 | 261 | 0.170 |
Why?
| | Biometry | 1 | 2021 | 70 | 0.170 |
Why?
| | Eye Injuries | 1 | 2021 | 45 | 0.170 |
Why?
| | Vitrectomy | 1 | 2020 | 70 | 0.160 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 10 | 0.160 |
Why?
| | Tattooing | 1 | 2020 | 14 | 0.160 |
Why?
| | Dementia | 1 | 2023 | 259 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2023 | 289 | 0.160 |
Why?
| | Survival Rate | 1 | 2024 | 1972 | 0.160 |
Why?
| | Laser Therapy | 1 | 2021 | 130 | 0.160 |
Why?
| | HIV | 1 | 2020 | 234 | 0.160 |
Why?
| | Retinal Diseases | 1 | 2020 | 91 | 0.160 |
Why?
| | Macular Edema | 1 | 2020 | 43 | 0.160 |
Why?
| | Tissue Donors | 1 | 2022 | 425 | 0.160 |
Why?
| | Arthritis, Reactive | 1 | 2019 | 8 | 0.160 |
Why?
| | Risk Factors | 2 | 2024 | 10388 | 0.150 |
Why?
| | United States | 5 | 2023 | 14841 | 0.150 |
Why?
| | Postoperative Period | 1 | 2020 | 342 | 0.150 |
Why?
| | Education, Medical, Graduate | 1 | 2023 | 486 | 0.150 |
Why?
| | Uveitis | 1 | 2020 | 136 | 0.150 |
Why?
| | Prosthesis Design | 1 | 2020 | 327 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 331 | 0.140 |
Why?
| | Biopsy | 2 | 2020 | 1129 | 0.130 |
Why?
| | Epithelium, Corneal | 1 | 2017 | 41 | 0.130 |
Why?
| | Ultrasonography | 1 | 2020 | 759 | 0.130 |
Why?
| | Curriculum | 1 | 2023 | 992 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2023 | 654 | 0.130 |
Why?
| | Adult | 7 | 2020 | 37929 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1483 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2022 | 3556 | 0.110 |
Why?
| | Aldehyde Reductase | 1 | 2013 | 29 | 0.110 |
Why?
| | Cell-Penetrating Peptides | 1 | 2013 | 21 | 0.110 |
Why?
| | Protein Structure, Quaternary | 1 | 2013 | 128 | 0.100 |
Why?
| | Blood Platelets | 1 | 2017 | 408 | 0.100 |
Why?
| | Immunosuppressive Agents | 1 | 2017 | 890 | 0.090 |
Why?
| | Cell Death | 1 | 2013 | 374 | 0.090 |
Why?
| | Cell Line | 2 | 2017 | 2847 | 0.090 |
Why?
| | Cell Survival | 1 | 2013 | 1120 | 0.080 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1353 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1809 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 545 | 0.080 |
Why?
| | Oxygen Inhalation Therapy | 1 | 1987 | 157 | 0.060 |
Why?
| | Intubation, Intratracheal | 1 | 1987 | 257 | 0.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2008 | 262 | 0.060 |
Why?
| | Video Recording | 1 | 2025 | 180 | 0.050 |
Why?
| | Safety-net Providers | 1 | 2023 | 119 | 0.050 |
Why?
| | Dissent and Disputes | 1 | 2021 | 20 | 0.040 |
Why?
| | Crowding | 1 | 2021 | 35 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2020 | 56 | 0.040 |
Why?
| | Adalimumab | 1 | 2020 | 48 | 0.040 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 31 | 0.040 |
Why?
| | Steroids | 1 | 2020 | 167 | 0.040 |
Why?
| | Health Surveys | 1 | 2021 | 514 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 546 | 0.040 |
Why?
| | Software | 1 | 2023 | 665 | 0.040 |
Why?
| | Cell Extracts | 1 | 2017 | 21 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2017 | 39 | 0.030 |
Why?
| | Mutation | 1 | 2008 | 3958 | 0.030 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2017 | 93 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2017 | 165 | 0.030 |
Why?
| | Cattle | 1 | 2017 | 984 | 0.030 |
Why?
| | Wound Healing | 1 | 2017 | 331 | 0.030 |
Why?
| | Colorado | 1 | 2023 | 4565 | 0.030 |
Why?
| | Cell Movement | 1 | 2017 | 967 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1291 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5472 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2486 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6828 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2475 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2017 | 1991 | 0.020 |
Why?
| | TRPP Cation Channels | 1 | 2008 | 85 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1987 | 180 | 0.020 |
Why?
| | Rest | 1 | 1987 | 121 | 0.020 |
Why?
| | Physical Exertion | 1 | 1987 | 215 | 0.020 |
Why?
| | Genetic Testing | 1 | 2008 | 460 | 0.010 |
Why?
| | Hypoxia | 1 | 1987 | 1112 | 0.010 |
Why?
| | Animals | 1 | 2017 | 36940 | 0.010 |
Why?
| | Young Adult | 1 | 2008 | 13209 | 0.010 |
Why?
|
|
Christopher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|